drugset
drugset / Trial / NCT04656951

Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse

NCT04656951 ↗

Phase 2 Active not recruiting 67 enrolled University of Cologne Janssen-Cilag G.m.b.H · collab
NaSingle-groupOpen-labelTreatment

Summary

Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA)

Timeline

Start
2021-06-01
Primary completion
2025-03-15
Completion
2031-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Daratumumab Monoclonal antibody 1800 mg Subcutaneous

Indications

plasma cell myeloma